Skip to main content
GLAND · Health Care · 2026-08-21

Gland Pharma Ltd

8.0★★★ PrimeStrong +13.2Stage 2 · wk 12In scan: Breakout WatchMARKET: BULL RISING · 2026-08-21
₹2,819.3
-0.02% today
₹46,509 Cr · Large cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro-intestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain/analgesics, respiratory and pulmonology, and vitamins, minerals, and nutrients. In addition, it provides contract development, dossier compilation, technology transfer services. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Visit company website →
P/E (TTM)
37.1
Forward 25.4
Earnings Growth (YoY)
+96.4%
Revenue +22.3%
ROE
+10.5%
Profit margin +16.0%
Dividend Yield
0.87%
P/B 4.0
vs 52W High
-5.1%
₹1,596.8 lo₹2,970.2 hi
5.1% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 12
1w13w26w
Week 12 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
41.4%
200 DMA: ₹1,994.2 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.30x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
MA20 trending up · +8.3% vs MA50 +8.0%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
This stock ranks #21 of 84 Stage 2 stocks in Health Care by RS.
Industry
Pharmaceuticals
↑ Building
Stage 2%
56.1%
20d Δ
+5.6pp
1M return
+2.7%
3M return
+10.4%
Industry Stage-2 % · last 20 days
Ranks #18 of 58 Stage 2 stocks in this industry.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-26 → 2026-08-21
S2 15w
S2 17w
S4 20w
S2 15w
2023-05-262026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 11w → S1 4w → S2 10w → S3 2w → S2 15w → S3 12w → S2 17w → S3 2w → S4 11w → S1 4w → S4 20w → S1 3w → S2 15w → S3 11w → S4 6w → S1 6w → S4 7w → S1 1w → S2 12w current
Total tracked: 169 weeks across 19 stage runs.
1M
+18.6%
3M
+20.8%
6M
+55.9%
YTD
+70.5%
1Y
+47.2%
Scan Membership
Breakout Watch
Latest: 2026-05-29
3 appearances in last 60 days. First seen: 2024-06-06.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S2
Wk 12 · Vol x
2026-08-20S2
Wk 12 · Vol x
2026-08-19S2
Wk 12 · Vol x
2026-08-18S2
Wk 12 · Vol x
2026-08-17S2
Wk 12 · Vol x
2026-08-14S2
Wk 11 · Vol x
2026-08-13S2
Wk 11 · Vol x
2026-08-12S2
Wk 11 · Vol x
2026-08-11S2
Wk 11 · Vol x
2026-08-10S2
Wk 11 · Vol x
2026-08-07S2
Wk 10 · Vol x
2026-08-06S2
Wk 10 · Vol x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹2,512.3
200 DMA
₹1,994.2
52W High
₹2,970.2
52W Low
₹1,596.8
5D Low
₹2,819.3
Resistance levels (recent highs)
20d High
₹2,970.2
60d High
₹2,970.2
120d High
₹2,970.2
250d High
₹2,970.2
Next resistance
+5.4%
to 20d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.